Kineta and Rosa form strategic alliance for next stage of clinical development of lead drug candidate...

Kineta, Inc. announced today a strategic alliance with Rosa to create pharmacokinetic/pharmacodynamics (PK/PD) models of Kineta’s lead drug compound, Shk-186, to estimate an optimal dose and dose frequency for humans in preparation for upcoming multi-dose clinical trials. Shk-186 is a novel, immune-sparing, targeted therapeutic focused on autoimmune diseases. (press release)